UZ Leuven

Contact: Prof. I Vergote

Ovarium

• A Phase 1b Study of AMG 386 in Combination with Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects with Advanced Recurrent Epithelial Ovarian Cancer
• A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian Cancer
• A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse
• An Open, Randomized, Multicenter Study in Patients with Recurrent Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficacy and Safety of paclitaxel (micellar) nanoparticles and paclitaxel(Cremophor® EL)
• STEALTH Liposomal doxorubicin vs Carboplatin/paclitaxel in patients with ovarian cancer recurrence between six and twelve months after previous platinum based chemotherapy: phase III multicenter randomized study
• Lymphadenectomy In Ovarian Neoplasms
• Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer
• A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors 
• A phase 1b open-label, multi-center study of AMG 386 in combination with paclitaxel and carboplatin in subjects with high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal or fallopian tube cancers
•  Phase I study of oral administration of S 78454 given with a fixed dose infusion of pegylated liposomal doxorubicin in the treatment of primary platinum-resistant and partially platinum-sensitive, epithelial ovarian, fallopian tube or primary peritoneal carcinoma
• A randomized, double-blind, placebo-controlled study of the efficacy and safety of MORAb-003 (farletuzumab) in combination with paclitaxel therapy in subjects with platinum-resistant or refractory relapsed ovarian cancer
• A phase I, randomised, 2 period cross over study to determine the comparative bioavailability of two different oral formulations of AZD2281 in cancer patients with advanced solid tumours
• A Phase 2, Multi-Center, Double-Blind, placebo controlled, Randomized Study of Ombrabulin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer treated with Carboplatin/Paclitaxel
• Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer

Cervix

• Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs concomitant radiotherapy and chemotherapy in FIGO stage IIB cervical cancer.
• A prospective, randomized phase III study to compare the effects of Paclitaxel and Topotecan to those of Cisplatin and Topotecan for treatment of patients with recurrent or persistent cervical cancer

 Endometrium

• A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy
• A Phase II International Multicentre Randomised Open Label Study of Oral Steroid Sulphatase Inhibitor BN83495 vs Megestrol Acetate (MA) in Women with Advanced or Recurrent Endometrial Cancer
• A phase 2 study of XL147 in subjects with advanced or recurrent endometrial carcinoma
• WTI immunotherapie bij uteriene tumoren, zowel carcinomen als sarcomen
• Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer
• A Phase II, single-arm study of orally administered BKM120 as second-line therapy in patients with advanced endometrial carcinoma
• An Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy

Vulva 

• GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) II
• Paclitaxel/Carboplatinum  bij locally advanced of gemetastaseerd vulvacarcinoma.

• Print
• Stuur door